Shares of Ocugen (OCGN) jumped after the drugmaker said it entered a development-and-supply agreement with Bharat Biotech tied to Ocugen's Covid-19 vaccine candidate.
In a Securities and Exchange Commission 8K filing, Ocugen said Bharat will supply it with clinical-trial materials and, if the drug is cleared by regulators, commercial supplies of finished drug product and drug components.
Shares of Ocugen, Malvern, Pa., at last check were 7% higher at $7.22. Bharat is the Hyderabad, India, biotechnology company.
Ocugen also said in the SEC filing that it entered an amended accord with development partner CanSino Biologics. The agreement is tied to Ocugen's gene-therapy candidate, OCU410, to treat dry age-related macular degeneration.
Under the amended accord, the companies will collaborate to develop OCU410. CanSino, the Tianjin, China, vaccine producer, will be responsible for the chemistry, manufacturing and controls of the clinical supplies.
精彩评论